Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $25
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:NDRA) with a Buy and lowers the price target from $27 to $25.
Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:NDRA) with a Buy and lowers the price target from $27 to $25.